Bio-Path Holdings Files 8-K
Ticker: BPTH · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: BPTH
TL;DR
BPTH filed an 8-K on Jan 10, 2025, with Reg FD disclosure and exhibits.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on January 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry and is headquartered in Bellaire, Texas.
Why It Matters
This filing indicates that Bio-Path Holdings, Inc. has made a regulatory disclosure and submitted financial exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures and exhibits without immediate material financial impact.
Key Numbers
- 001-36333 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-0652870 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- January 10, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Bellaire, Texas (location) — Principal Executive Offices
FAQ
What specific information is included in the Regulation FD Disclosure?
The filing does not specify the exact content of the Regulation FD Disclosure, only that it was made on January 10, 2025.
What are the key exhibits filed with this 8-K?
The filing indicates that Financial Statements and Exhibits were submitted, but the specific list of exhibits is not detailed in this summary.
When was Bio-Path Holdings, Inc. incorporated?
Bio-Path Holdings, Inc. was incorporated in Delaware.
What is the primary business of Bio-Path Holdings, Inc.?
Bio-Path Holdings, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What is the address of Bio-Path Holdings, Inc.'s principal executive offices?
The principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-01-10 16:15:24
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20250110x8k.htm (8-K) — 39KB
- bpth-20250110xex99d1.htm (EX-99.1) — 27KB
- bpth-20250110xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-25-000123.txt ( ) — 206KB
- bpth-20250110.xsd (EX-101.SCH) — 3KB
- bpth-20250110_lab.xml (EX-101.LAB) — 16KB
- bpth-20250110_pre.xml (EX-101.PRE) — 10KB
- bpth-20250110x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 10, 2025, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Provides 2025 Clinical and Operational Update." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated January 10, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: January 10, 2025 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer